Document is current

Article History

Received: 1 July 2024

Accepted: 25 October 2024

First Online: 17 November 2024

Declarations

:

: The experimental protocol was approved by the European Animal Care Legislation (2010/63/EU), by the Italian Ministry of Health in accordance with the D.L. 116/1992 and by the guidelines of the University of Genova (Prot. 75F11.N.6JI, 08/08/2018). We received the Ngn2-positive and Ascl1-positive hiPSCs lines in frozen vials, kindly provided by Prof. Nadif Kasri (Radboud University Medical Centre, the Netherlands). The genetically modified organism (GMO) approval under which the lines have been used is IG22-071. The two lines provided by our collaborators were previously characterized []. The lines were infected, according to a previously published protocol [], with lentiviral constructs encoding rtTA combined with Ngn2 (Control line 1) or Ascl1 (Control line 2) to generate doxycycline-inducible excitatory or inhibitory neurons arrays [, ]. Both lines were generated from reprogrammed fibroblasts. Control line 1 (C1, healthy 30-years-old female, Ngn2) was reprogrammed via episomal reprogramming (Coriell Institute for medical research, GM25256). Control line 2 (C2, healthy 51-years-old male, Ascl1) was reprogrammed via a non-integrating Sendai virus (KULSTEM iPSC core facility Leuven, Belgium, KSF-16-025). Karyotypes of hiPSCs lines were verified, and hiPSCs lines were tested for pluripotency and genomic integrity based on single nucleotide polymorphism arrays [, ]. We declare that the research was conducted in accordance with the principles embodied in the Declaration of Helsinki and in accordance with local statutory requirements.

: Not applicable.

: The authors declare that they have no competing interests.